|
06 Apr 2020 |
Initiation of two-centre compassionate use study involving namilumab in the treatment of individual patients with rapidly worsening COVID-19 infection in Italy
|
|
06 Apr 2020 |
Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium
|
|
06 Apr 2020 |
FDA clears investigational new drug application for mesoblast to use remestemcel-L in patients with acute respiratory distress syndrome caused by COVID-19
|
|
04 Apr 2020 |
ORYZON Presents Efficacy Data From its Two Vafidemstat Clinical Trials in Alzheimer’s Disease at the Virtual AAT-AD/PD 2020 Conference
|
|
04 Apr 2020 |
I-Mab Announces IND Clearance from FDA for TJM2 to Treat Cytokine Release Syndrome (CRS) Associated with Severe Coronavirus Disease 19 (COVID-19)
|
|
04 Apr 2020 |
XBiotech and BioBridge Global Collaborate on FDA Program to Develop Potential COVID-19 Treatment Based on Natural Antibodies from Recovered Patients
|
|
04 Apr 2020 |
Gracell Announces China NMPA Acceptance of Investigational New Drug Application for GC007g Cell Therapy for CD19 Positive Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
|
|
04 Apr 2020 |
Axon Presented Positive Phase II Trial Results of AADvac1 at AAT-AD/PD 2020
|
|
04 Apr 2020 |
UroGen Announces Positive Interim Data from Phase 2b Study of UGN-102 in Patients with Low-Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer
|
|
04 Apr 2020 |
Nucala (mepolizumab) is the first anti-IL5 biologic to report positive phase 3 results in patients with nasal polyps
|
|
04 Apr 2020 |
Update on GSK actions to support the global response to COVID-19
|
|
04 Apr 2020 |
Servier signed a definitive agreement to acquire Symphogen, a leading antibody discovery company, to boost its antibody capabilities and leverage its R&D pipeline
|
|
04 Apr 2020 |
panCELLa Extends Exclusive License to Astellas
|
|
04 Apr 2020 |
Dupixent® (dupilumab) Phase 3 data show significant improvement in severe atopic dermatitis for children aged 6 to 11 years
|
|
04 Apr 2020 |
Rybelsus® (oral semaglutide) approved for the treatment of adults with type 2 diabetes in the EU
|
|
04 Apr 2020 |
U.S. Food and Drug Administration (FDA) Approves Reblozyl® (luspatercept-aamt) , the First and Only Erythroid Maturation Agent, to Treat Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
|
|
03 Apr 2020 |
Biotest is developing with Trimodulin a COVID-19 therapy for patients with a severe course of the disease
|
|
03 Apr 2020 |
Fate Therapeutics Announces Worldwide Collaboration with Janssen for Novel iPSC-derived Cell-based Cancer Immunotherapies
|
|
03 Apr 2020 |
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
|
|
03 Apr 2020 |
Henlius Novel Anti-EGFR Monoclonal Antibody Demonstrated Favorable Safety and Tolerability Profile in Its Phase 1 Clinical Study
|
